Cellivery's Autoimmune Disease Treatment 'iCP-NI'... "Proven Efficacy for Atopic Dermatitis by US CRO"
[Asia Economy Reporter Hyunseok Yoo] Cellivery announced on the 26th that its innate immune therapy iCP-NI, developed in the United States, has successfully proven efficacy in atopic dermatitis treatment at a level suitable for clinical development in efficacy evaluations conducted by the global contract efficacy evaluation organization MLM Medical Labs.
Jae-Hyun Kim, Head of Autoimmune Disease Development at Cellivery, stated, “According to the recent analysis results of the atopic dermatitis efficacy test from the global new drug efficacy evaluation organization MLM, iCP-NI showed over 60% treatment efficacy on the 'Atopic Dermatitis Severity Index,' which is the efficacy evaluation indicator for atopic dermatitis treatment.”
He added, “Currently, additional tests are underway with an optimized protocol to increase the atopic dermatitis treatment efficacy from about 60% to over 80%, and we are verifying not only the Atopic Dermatitis Severity Index but also the inflammation control efficacy in skin tissues. Once the ointment formulation toxicity test is completed, the non-clinical trials can be finished within this year, and entry into clinical trials in the United States will become visible.”
In previous efficacy evaluations of iCP-NI in atopic dermatitis animal models, Cellivery reduced inflammation-inducing immune T cells by more than 50%. The secretion of the most potent inflammation-inducing cytokines, tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and immunoglobulin E (IgE), which induces allergic reactions, was also reduced by 87%, 66%, and 71%, respectively.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- The Second Donghak Ant Movement? ... Individual Investors Keep Buying Despite Foreign Sell-Offs [1-Minute Brief]
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Daewoong Cho, CEO of Cellivery, said, “Since iCP-NI has already demonstrated anti-inflammatory immune control efficacy and safety as a COVID-19 immune therapy in the United States, we will promptly proceed with clinical development as an autoimmune atopic dermatitis treatment, which is another indication.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
